Study Title: The effect of a single-dose of d-cycloserine on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized placebo-controlled trial

EudraCT Number: 2012-003191-39

For a full description of objectives, methods and results see:
Biorxiv doi: 10.1101/2019/615757.

Table 1. Primary and secondary outcomes at baseline, on the day after treatment, and at 1-month and 6-months follow-ups.

		PLACEBO	D-CYCLOSERINE	Adjusted mean diff (SE)	95% CI, p-value, Cohen's d
FDOT (fear)	Next-Day	21.3 (30.8)	2.1 (17.2)	-19.0 (9.3)	-38.04 to 0.14; **p=0.042**; d=0.77
Right Amygdala	Next-Day	0.25 (0.27)	-0.08 (0.35)	-0.32 (0.14)	-0.61 to -0.03; **p=0.023**; d=1.06
Left Amygdala	Next-Day	0.17 (0.33)	0.05 (0.68)	-0.12 (0.19)	-0.50 to 0.27; p=0.54; d=0.22
STAI-S (20-80)	Baseline	42.8 (7.3)	43.9 (12.5)	..	..
	Next-Day	44.9 (8.8)	34.6 (11.0)	-10.67 (3.57)	-17.83 to -3.51; **p=0.0041; d=1.01**
	1-month	39.7 (9.2)	32.2 (10.9)	-7.92 (3.71)	-15.30 to -0.54; **p=0.036**; d=0.74
	6-months	38.9 (12.8)	31.4 (9.7)	-8.05 (3.95)	-15.94 to -0.16; **p=.046**; d=0.66
STAI-T (20-80)	Baseline	52.2 (6.7)	52.4 (9.4)	..	..
	Next-Day	50.8 (8.3)	47.1 (10.7)	-3.53 (3.60)	-10.74 to 3.68; p=0.33; d=0.39
	1-month	46.3 (11.8)	38.2 (12.6)	-7.99 (3.74)	-15.44 to -0.54; **p=0.036**; d=0.66
	6-months	44.4 (12.8)	35.2 (10.3)	-9.20 (3.89)	-16.96 to -1.44; **p=0.021**; d=0.79
BDI (0-63)	Baseline	16.8 (9.4)	17.3 (11.7)	..	..

	Next-Day	18.3 (10.1)	13.2 (10.0)	-5.26 (2.46)	-10.19 to -0.33; **p=0.037**; d=0.51
	1-month	12.5 (8.0)	11.1 (10.4)	-1.57 (2.56)	-6.66 to 3.53; p=0.54; d=0.15
	6-months	12.0 (10.1)	6.3 (6.6)	-5.86 (2.72)	-11.29 to -0.42; **p=0.035**; d=0.67
ACQ Baseline	**(1.0-5.0)**	2.5 (0.5)	2.4 (0.7)	..	..
	Next-Day	2.6 (0.5)	2.3 (0.6)	-0.21 (0.19)	-0.60 to 0.17; p=0.27; d=0.30
	1-month	2.2 (0.7)	1.9 (0.7)	-0.29 (0.20)	-0.69 to 0.11; p=0.16; d=0.43
	6-months	2.0 (0.7)	1.6 (0.6)	-0.37 (0.22)	-0.81 to 0.07; p=0.095; d=0.61
BSQ Baseline	**(1.0-5.0)**	3.2 (0.8)	3.2 (0.7)	..	..
	Next-Day	3.2 (0.8)	3.0 (0.8)	-0.12 (0.27)	-0.66 to 0.41; p=0.65; d=0.14
	1-month	2.6 (0.8)	2.5 (0.8)	-0.06 (0.27)	-0.60 to 0.48; p=0.82; d=0.13
	6-months	2.4 (1.0)	2.2 (1.0)	-0.12 (0.29)	-0.71 to 0.47; p=0.68; d=0.20
MI (1.0-5.0)	Baseline	2.3 (0.7)	2.1 (0.9)	..	..
	Next-Day	2.2 (0.5)	2.1 (0.8)	-0.038 (0.16)	-0.35 to 0.27; p=0.81; d=0.15
	1-month	1.9 (0.6)	1.7 (0.8)	-0.12 (0.16)	-0.43 to 0.20; p=0.46; d=0.28
	6-months	1.8 (0.5)	1.5 (0.6)	-0.18 (0.18)	-0.54 to 0.19; p=0.34; d=0.54
PAS (0-4)	Baseline	1.8 (1.1)	1.7 (1.2)	..	..
	Next-Day	1.8 (1.0)	1.5 (1.0)	-0.26 (0.27)	-0.79 to 0.27; p=0.33; d=0.30
	1-month	0.7 (0.8)	0.5 (1.0)	-0.22 (0.30)	-0.81 to 0.37; p=0.46; d=0.22
	6-months	0.5 (0.8)	0.3 (0.7)	-0.19 (0.30)	-0.79 to 0.40; p=0.52; d=0.27
PDSS Baseline	**(0-28)**	11.8 (4.0)	11.6 (4.6)	..	..
	1-month	6.1 (4.4)	4.8 (5.3)	-1.31 (1.39)	-4.11 to 1.48, p=0.35, d=0.27
	6-months	4.6 (3.8)	3.4 (3.8)	-1.19 (1.45)	-4.12 to 1.73, p=0.41; d=0.24
Stress Baseline	**(0-100)**	41.1 (25.9)	43.4 (24.7)	..	..
	Next-Day	29.2 (21.5)	17.8 (14.6)	-14.09 (4.55)	-23.0 to -5.1; **p=0.0021**; d=0.62
	1-month	19.1 (17.3)	13.0 (15.2)	-8.84 (4.63)	-17.9 to 0.3; p=0.057; d=0.37
	6-months	20.0 (22.0)	11.5 (15.6)	-11.20 (4.67)	-20.4 -2.0; **p=0.017**; d=0.45

Note: FDOT = Faces Dot Probe Task; IAT = Implicit Association Task; STAIS/ STAIT = state trait anxiety inventory; BDI = Beck Depression Inventory; ACQ = Agoraphobic Cognitions Questionnaire; BSQ = Body Sensations Questionnaire; MI = Mobility Inventory; PAS = Panic Attack Scale; PDSS = Panic Disorder Severity Scale.